Revagenix leverages a lean team to deliver results equivalent to a company several times our size. Through a world-class network of strategic collaborators, partners, investors, and advisors we’ve created a meta-team capable of delivering the next generation of antibiotics.

Ryan Cirz, PhD


Andrew McCandlish, PhD


Daniel Cloutier, PharmD

VP, Development

Mick Hurrey, PhD

VP, Pharmaceutical Development

Tina Marriott

Board Chair

President & COO, Recursion

Cristina Larkin

Founder, CLC Insights

Michael Lamprecht, PhD


Bruce Montgomery, MD

Representative, Novo Holdings

Ryan Cirz, PhD

Co-founder & CEO

Andrew McCandlish, PhD

Co-founder & COO

Lloyd Czaplewski

CSO, Persica Pharmaceuticals

Director, Chemical Biology Ventures

Chair, Novo Repair Impact Scientific Selection Board

Ian Friedland, MD

Strategic Consultant, Medical and Development

J. Kevin Judice, PhD

CEO, DICE Therapeutics

Heinz Moser, PhD

Executive Director, Global Discovery Chemistry, Novartis Institutes for Biomedical Research


Novo Holdings

National Institute of Allergy and Infectious Diseases (NIAID)